Ovarian Cancer Articles | Page 3

Clinical Impact of Chronic Low-Grade Nausea Is Woefully Underestimated
Antineoplastic drug therapy has been delivered by the oral route since the earliest days of the modern chemotherapeutic era.
The FDA has accepted a supplemental biologics license application for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer.
FDA Approval Sought for Maintenance Rucaparib in Ovarian Cancer
A supplemental new drug application has been submitted to the FDA for rucaparib as maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Molecular Techniques Help Identify Ovarian Cancer Recurrence
Peter Dottino, MD, discusses the utilization of molecular methods to identify ovarian cancer following treatment with chemotherapy, and how this type of research impacts the field going forward.
Testing Beyond BRCA a Growing Approach in Ovarian Cancer Families
Ophira Ginsburg, MD, discusses hereditary ovarian cancer, the occasional reluctance in testing, multigene panels, and the understanding of variants of uncertain significance.
Expert Highlights Immunotherapy Potential in Ovarian Cancer
Dmitriy Zamarin, MD, PhD, discusses immunotherapy for patients with ovarian cancer.
PARP Inhibitors Have Potential to Benefit Larger Patient Populations in Ovarian Cancer
Bhavana Pothuri, MD, discusses the available PARP inhibitors and ongoing trials further investigating these agents in ovarian cancer.
Precision Medicine Rapidly Being Incorporated Into Ovarian Cancer Care
Douglas A. Levine, MD, shared his insight on how the ovarian cancer landscape has developed a more personalized treatment approach.
Combined Niraparib and Bevacizumab Shows Promising Activity in Recurrent Ovarian Cancer
The combination of bevacizumab plus niraparib demonstrated clinical activity in women with relapsed, platinum-sensitive epithelial ovarian cancer and had a manageable toxicity profile.
Maintenance Rucaparib Highly Effective Across Ovarian Cancer Subtypes
Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.
Publication Bottom Border
Border Publication